Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
15-valent HPV vaccine in healthy Chinese people aged 9-45 years
NCT06756269Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Countries
- 1
- Modality
- Vaccines & Immunotherapeutics
- Conditions
- human papillomavirus infectionHPV-related carcinomaHuman papillomavirus–related intraepithelial neoplasia (HPV-IN)genital warts
01
Overview
Phase 2, randomised, double-blind trial of 15-valent human papillomavirus recombinant vaccine in human papillomavirus infection, HPV-related carcinoma, Human papillomavirus–related intraepithelial neoplasia (HPV-IN) and 1 more (4 arms), sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoints: Adverse Events at 30 minutes, Solicited Adverse Events at 14 days and 3 more. Started Jan 2025; status: recruiting.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Medium dose 15-HPV vaccine
Medium dose 15-valent HPV vaccine at 0, 2, 6 months
High dose 15-HPV vaccine
High dose 15-valent HPV vaccine at 0, 2, 6 months
Placebo
Placebo at 0, 2, 6 months
9-HPV vaccine
9-valent HPV vaccine at 0, 2, 6 months (active comparator, 18-45 years only)
03
Who it enrols
Healthy Chinese participants aged 9-45 years with no prior HPV vaccination, no history of HPV infection or related diseases, no immunodeficiency or autoimmune conditions, and no recent vaccination or immunosuppressive therapy
04
Endpoints
Primary
Adverse Events
Solicited Adverse Events
Unsolicited Adverse Events
Serious Adverse Events
Pregnancy Events
Secondary
Immunogenicity after receiving 3 doses of 15-HPV vaccine
Beyond the preview
Go deeper on NCT06756269.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756269.